Connect with us

Cannabis News

Nebraska Legislature Approves Bill To Protect Doctors Who Recommend Medical Marijuana

Published

on

“Today is a small step forward, but we are facing terrible prospects.”

Zach Wendling, Nebraska Examiner

Health care Practitioners wishing to recommend medical cannabis to patients in Nebraska They are one step closer to having legal protections to write the recommendation in the face of opposition from some state leaders.

The Legislature voted 30-7 Friday to advance House Bill 933 by state Sen. John Cavanaugh of Omaha. It would protect medical providers from criminal, civil or disciplinary penalties “merely” for providing a written recommendation or stating that, in their professional opinion, the potential benefits of cannabis outweigh the potential harms.

“It would create a step forward and hope and opportunity for these families who have worked so hard, waited so long and would like to have that conversation with their doctors and then get some relief,” Cavanaugh said during the discussion.

Legislators clarified that the practitioner would not be protected from malpractice or professional negligence claims, such as failing to evaluate a patient or follow an appropriate standard of care. A Cavanaugh amendment passed 35-4, as did a similar amendment from the House Health and Human Services Committee on a 38-4 vote.

State Sen. Brian Hardin Gering, chairman of the HHS Committee, opposed LB 933 in committee, but said the added language was an “important clarification.”

“Practitioners are protected by the recommendation itself, but they are responsible for conducting a thorough and appropriate assessment of the patient before making it,” Hardin said.

“Professional malpractice or negligence” is defined in law as failure to use “ordinary and reasonable care, skill and knowledge normally possessed and exercised by members of his profession engaged in similar activities in the same or similar countries.”

In the 2024 general election, 71% of voters supported a recommendation to legalize the possession of 5 ounces of medical cannabis, and 67% of voters created the Nebraska Medical Cannabis Commission.

Reaching 33 votes

Similar protections for providers were included in a bill offering a broader regulatory framework proposed in 2025, LB 677 by state Sen. Ben Hansen of Blair. The bill failed 23-22, missing the 33 votes needed to overcome a filibuster.

Cavanaugh’s LB 933 would also need 33 votes to change voter-approved laws, as required by the Nebraska Constitution.

There is still a way to get there, with 12 senators absent or absent from Friday’s vote. One of them, State Sen. Rick Holdcroft of Bellevue, who was “absent, did not vote,” supported LB 677 10 months ago but did not vote to advance LB 933. He is the only supporter of LB 677 on that ship.

Holdcroft helped get LB 677 out of the General Affairs Committee as committee chair. He said his biggest concern last year was funding for the commission, which this year is being addressed by state budget adjustments LB 1071 and a separate General Affairs bill, LB 1235.

Holdcroft noted that the Medical Cannabis Board has just completed licensing four growers, and indicated that it could be eight months to a year before there is enough of a crop to manufacture and later distribute.

“To start giving immunity to doctors who are going to make recommendations for a product that we won’t even have for a year is, I think, a little premature,” Holdcroft said.

Cavanaugh, Hansen and other advocates say the protections are necessary for a state program to exist. So far, they said, no state doctor has made a recommendation, in part because of fear of retribution, such as from law enforcement. And without protection, supporters worry that there will be no patients able to access board-licensed facilities.

Nebraska Attorney General Mike Hilgers (R) rallied law enforcement against Hansen’s LB 677 in 2025 and spoke out against the health care professionals’ language. His office did not formally oppose LB 933, nor did the Nebraska Department of Health and Human Services.

“The preponderance of scientific evidence”

State Sen. Jared Storm of David City, who led the opposition to LB 677 last year, introduced an amendment to Cavanaugh’s bill requiring the health care professional’s recommendation to be “based on the preponderance of current scientific evidence.”

Storm argued that the “simple and straightforward addition” was rooted in the Hippocratic Oath “to do no harm.”

“If you’re against this amendment, you’re in favor of recreational marijuana,” Storm said. “If you’re in favor of my correction, you see this as medicine.”

Cavanaugh argued the opposite, that LB 933 It would protect advocates and not encourage them to rally in favor of recreational marijuana because of delays in access to medical marijuana. Hansen made a similar request last year.

“If you don’t want a recreational program, we have to make our medical program functional,” Cavanaugh said.

Storm, Hansen and Cavanaugh said they know of no doctors nationwide who have been sued for malpractice or negligence for recommending medicinal cannabis.

‘Moral hazard’ or ‘dangerous road’?

State Sens. Tanya Storer of Whitman and Bob Andersen of Sarpy County argued, as Storm did, that the debate was about public safety rather than medical cannabis.

Storer said, “Immunity creates moral hazard. When there are no consequences, there is less incentive to exercise caution.”

Cavanaugh and Hansen were concerned about the long-term effects of Ekaitz’s proposal, arguing that it “muddies the water.” Hansen said we could “go back and bite ourselves in the ass” over some drugs, such as Ivermectin, used in the COVID-19 pandemic.

Cavanaugh said he spoke with the Nebraska Medical Association and the association’s malpractice provider, and Cavanaugh told him that Storm’s amendment would “create more uncertainty.”

Hansen, the former chairman of the HHS Committee, said he understood where Storm was coming from and was aware of Storm’s views on medical cannabis. Hansen said using the “preponderance of scientific evidence” would rule out more than 38 percent of the drugs dispensed off-label.

“I think we’re going down a very dangerous path in the future in terms of micromanaging how a medical professional can prescribe medication in the future,” Hansen said.

‘A bit of fixer upper’

State Sen. Carolyn Bosn of Lincoln, a former prosecutor, clarified with Cavanaugh that nothing in LB 933 would protect a practitioner’s license if it went against their professional judgment. He said the legal standard is based on someone’s education, training and experience. He accepted protections.

Storm said one problem was the difference between a “recommendation” and a “prescription” for medical cannabis. For example, he noted, opioids are tracked under the state’s Prescription Drug Monitoring Program. Hansen proposed using this system in LB 677.

Hardin, who ultimately did not vote on advancing LB 933, said he supported Ekaitz’s amendment. He said they’ve studied marijuana “since they were crossing a mile from my house on the Oregon Trail,” and with dozens of states legalizing marijuana, how to ask that question “in the safest way possible.”

“I think it’s a little bit of a fix, and I think we’re getting there,” Hardin said.

The storm amendment failed 22-19. They may try again at a future debate, as five senators were absent from the state Capitol Friday, including Storer.

‘Small step forward’

Crista Eggers of Nebraskans for Medical Marijuana said she was encouraged by the progress of LB 933, but some of the debate, especially around Storm’s amendment, shows continued opposition to a functioning state program.

“It’s a small step forward today, but we face daunting prospects as this bill moves forward to select file and final reading,” Eggers said after the vote.

“Nebraskas have had few victories in this decades-long battle,” he continued. “Today is one of them.”

LB 933 has two more rounds of debate before it, with 33 votes it can send to Nebraska Governor Jim Pillen for his signature.

Vote to advance bill 933 related to medicinal cannabis

Yes (30): John Arch, Carolyn Bosn, Eliot Bostar*, Tom Brandt*, John Cavanaugh*, Machaela Cavanaugh*, Stan Clouse*, Danielle Conrad*, Wendy DeBoer*, Barry DeKay, Myron Dorn*, George Dungan*, John Fredrickson*, Dunixi Guereca*, Ben Hansen*, Jana Hughes*, Terrell*, Margo Juguez*, Margo Juguez McKinney*, Fred Meyer, Glen Meyer*, Jason Prokop*, Dan Quick*, Jane Raybould*, Merv Riepe, Victor Rountree*, Rita Sanders, Ashley Spivey, Brad von Gillern and Dave Wordekemper*.

No (7): Bob Andersen, Rob Clements, Mike Jacobson, Kathleen Kauth, Loren Lippincott, Dave Murman and Jared Storm.

Presented, not voted (7): Christy Armendariz, Beau Ballard, Brian Hardin, Rick Holdcroft*, Teresa Ibach, Mike Moser and Tony Sorrentino.

Sorry, no vote (5): Rob Dover, Bob Hallstrom, Dan Lonowski, Tanya Storer and Paul Strommen.

* Voted in favor of a broader scope of medical cannabis proposed in 2025 (Legislative Bill 677).

This story was first published by the Nebraska Examiner.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Redefining the standards of UK cannabis

Published

on

By

Dalgety Ltd has entered into a partnership with Curaleaf Laboratories to supply pharmaceutical grade cannabis medicines to the UK cannabis market. The arrangement combines Dalgety’s cultivation operations, which are certified to EU-GMP standards, with Curaleaf Laboratories’ pharmaceutical manufacturing and distribution capabilities. According to the companies, this creates a UK-based supply route that does not rely on imported cannabis flowers, as Dalgety cultivates its product in-house. Dalgety claims it was the first company in the UK to grow, manufacture and supply EU-GMP medical cannabis from a single site.

© Curaleaf Laboratories

The growing facility, which is more than 30,000 square feet, is located indoors and uses hydroponic growing methods along with automated lighting, irrigation, humidity and temperature control systems. The company reports that it uses AI-assisted environmental monitoring, which extends the traceability of batches to the final product and compares them to operating standards for air filtration systems. Post-harvest processing is said to follow EU-GMP protocols, including microbial and cannabinoid testing.

The stated goal of this approach is to reduce between-harvest variation in terms of THC and CBD content, terpene profiles, and microbial safety. Dalgety says his cultivation is overseen by staff with experience in horticulture and biochemistry, some of whom have worked on cannabis cultivation projects internationally.

Through a partnership with Curaleaf Laboratories, Dalgety’s UK-grown cannabis is processed and distributed through a UK-based supply chain, rather than imported from overseas. Companies suggest that this arrangement can shorten the time it takes to get products to market compared to importing, and reduce the likelihood of supply disruptions. Because Dalgety and Curaleaf Laboratories are involved in cultivation, manufacturing and distribution, the companies say this oversees the product at every stage, making it clearer for prescribers to see where and how the product was made.

© Curaleaf Laboratories

Dalgety operates to EU-GMP standards and has been subject to regulatory review by the MHRA and the Home Office. Its operations include environmental monitoring, microbial testing, stability testing, controlled drying and curing procedures and quality assurance processes, along with controlled and secure facilities.

The company describes its work as controlled environment farming, hydroponic systems, environmental control technology, and efforts to stabilize cannabis genetics and phenotypes for batch-to-batch consistency.

© Curaleaf Laboratories

Dalgety has also opened its cultivation facilities for visits to healthcare professionals, clinicians, pharmacists, researchers and other industry stakeholders. The company says this is in response to the fact that much of the cannabis historically supplied to UK patients has been grown overseas, which has limited opportunities for UK clinicians to see first-hand the cultivation and quality control processes. These tours aim to provide visitors with information on cultivation standards, EU-GMP compliance procedures, environmental control systems, testing processes and the regulatory framework governing cannabis manufacturing in the UK.

Dalgety and Curaleaf Laboratories describe their partnership as expanding access to UK-grown medical cannabis, improving supply chain reliability and helping to meet sector regulations, placing it in the wider context of growing demand for cannabis-based treatments from UK patients.

For more information:
Curaleaf Laboratories
Email: (email protected)
https://curaleaflaboratories.co.uk/

Continue Reading

Cannabis News

Arkansas GOP Governor And Democratic Challenger Agree On Opposing Marijuana Legalization

Published

on

By

“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans.”

Antoinette Grajeda, Arkansas attorney

Contains medical marijuana It generated more than $1 billion since Arkansas voters legalized it in 2016

After the state opened its first dispensary in 2019, thousands of Arkansans joined the program and spent a record $291.1 million on medical marijuana in 2025, according to the state Department of Finance and Administration.

Tax revenue from those sales now supports free breakfast for public school students after lawmakers passed legislation last year.

Medical marijuana programs have expanded across the country, as has recreational marijuana. Two dozen states, including neighboring Missouri, allow recreational marijuana use, according to state legislatures.

Arkansas voters rejected an effort to legalize recreational marijuana in 2022despite the national teams spending millions in support of the measure.

Restrictions on marijuana have been relaxed at the federal level, and the US Department of Justice earlier this year downgraded the drug classification of medicinal cannabis.

Here’s what Arkansas’ gubernatorial candidates — Democratic State Sen. Fred Love, Republican Gov. Sarah Huckabee Sanders and Libertarian Colt Shelby — have to say about legalizing recreational marijuana.

Democratic State Sen. Fred Love

Love said he opposes legalization during a debate at the Arkansas Press Association’s annual conference in June.

Sitting in a crosswalk at her daughter’s school, Love said “marijuana is all over” as the children exited their vehicles. When you grow up in a community where recreational marijuana is present, you see that it doesn’t always have a positive effect, he said.

“I don’t think it’s something I support,” Love said. “I’ve seen the long-term impact.”

While he doesn’t personally support it, Love said he would support legalizing recreational marijuana if Arkansans voted on it.

Libertarian Colt Shelby

Shelby said he’s for whatever Arkansans want, so he would support legalizing recreational marijuana if voters approve.

Shelby said the state’s elected officials have forgotten what matters most is what Arkansans want, which is why she’s running for office.

Although Shelby says she doesn’t smoke weed herself, she says almost everyone knows it and she has the meds.

“It brings a lot of good things, so I won’t say that I’m against it, but let the people decide”, he said in the debate in June.

Republican Governor Sarah Huckabee Sanders

Sanders did not participate in the June debate, but said in an emailed statement that he does not support the legalization of recreational marijuana.

“Giving more access to drugs, especially recreational access, does nothing to help or benefit Arkansans,” Sanders said.

Sanders vetoed a law passed by the Legislature last year dispensaries have been allowed to deliver orders via a delivery vehicle or drive-through window.

The governor signed into law in 2023 the bill protecting the rights for medical marijuana patients and caregivers to obtain a license to carry a concealed handgun.

In 2025, Sanders backed that uses medical marijuana revenue to support free breakfast for all public school students.

This story was first published by the Arkansas Advocate.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Will the top World Cup expert in the fruit, vegetable, and horticulture sector come from Canada, the U.S. or Belgium?

Published

on

By






FreshPublishers 2026 World Cup Group Stage






The World Cup is coming to an end, with the third-place play-off between France and England on Saturday, and the final between Spain and Argentina the following day. It won’t be long until the grand winner of FreshPublishers’ first World Cup pool is revealed.

© Fresh Publishers

As previously reported, Slim Kooli from Courchesne Laros is the favorite to win the €1,000 prize. He has secured a comfortable lead over Nol Batist of North American Interstate Greenhouse Company, while buyer Bjorn Van Ryckeghem of Deprez Construct is currently in third place.

1 Sim School Spain 1–0 2–1 737 9716
2 Nol Batist France 2–1 1–1 674 9433
3 Bjorn Van Ryckeghem France 2–2 3–1 674 9264
4 Christian Anton Smedshaug England 1–2 1–2 659 9134
5 Perry Springintveld Spain 1–1 2–1 647 9105
6 Willem Tijssen Spain 2–0 2–1 710 9098
7 Hans Borsboom Spain 2–1 2–1 528 9058
8 Bart Triemstra Spain 2–1 2–1 737 9052
9 Youness Bensaid Spain 2–1 1–1 722 8954
10 Vijay Dijkstra Portugal 2–0 2–1 382 8953

However, there have been some surprises during the tournament, and bonus points must be added, so we will keep the suspense a little longer. On Monday we will find out who is the main World Cup announcer in the international fruit, vegetable and horticulture sector…



Publication date:













Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media